SCHEMBL23218696

SCHEMBL23218696

CCCc1oc2ccc(Br)cc2c1C(=O)OC

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
TP53 P04637 3/20 0.49
TSHR P16473 4/20 0.49
HSD11B1 P28845 1/20 0.47
PLK1 P53350 1/20 0.46
HSD17B10 Q99714 3/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
CA12 O43570 2/20 0.45
CA9 Q16790 2/20 0.45
ALOX5 P09917 3/20 0.45
HTT P42858 1/20 0.44
CYP2C9 P11712 2/20 0.43
SLC22A12 Q96S37 1/20 0.43
EYA3 Q99504 1/20 0.43
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853044 1.00 MAPT (0.49) MAPTTP53TSHRHSD11B1PLK1
SCHEMBL29852438 0.89 SLC22A12 (0.53) MAPTTP53TSHRHSD17B10KDM4E
SCHEMBL23218476 0.89 SLC22A12 (0.53) MAPTTP53TSHRHSD17B10KDM4E
SCHEMBL23218333 0.88 TSHR (0.48) MAPTTP53TSHRHSD17B10KDM4E
SCHEMBL29853212 0.88 TSHR (0.48) MAPTTP53TSHRHSD17B10KDM4E
SCHEMBL29853045 0.79 GAA (0.55) MAPTTP53TSHRHSD17B10KDM4E
SCHEMBL15020039 0.79 GAA (0.55) MAPTTP53TSHRHSD17B10KDM4E
SCHEMBL31485744 0.76 MAPT (0.69) MAPTTP53TSHRHSD11B1HSD17B10
SCHEMBL7390820 0.76 MAPT (0.60) MAPTTP53TSHRHSD17B10KDM4E
SCHEMBL23218840 0.76 SMN1; SMN2 (0.57) MAPTTP53TSHRHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAPT 4793/4885TP53 3891/4885TSHR 1199/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAPT 3561/4885TP53 3580/4885TSHR 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.